Affordable obesity drugs could bring seismic shift to health care, conference hears
Doctors back Ozempic-like drugs for wider health improvements at Global Healthspan Summit in Riyadh
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
6 days ago
- Zawya
Kilow launches Saudi Arabia's first integrated health marketplace for weight loss
Riyadh – Kilow, Saudi Arabia's leading digital health and weight loss platform, is proud to announce the official launch of Kilow Marketplace: a first-of-its-kind platform that brings together medical tools, lab testing, nutritional supplements, medications, and fitness essentials – all in one place to support users across every stage of their wellness journey. Kilow Marketplace marks a strategic milestone in Kilow's vision to provide a medically guided and fully integrated ecosystem for healthy, sustainable weight loss, especially for users on GLP-1 treatments such as Ozempic or Mounjaro. "We're not just offering products, we're building a smarter, more holistic experience around health. The marketplace connects users directly with the resources they need to succeed," said Fahad Al Essa, Founder and CEO of Kilow. Marketplace Highlights: Initial partnerships with Bioniq and a growing list of certified labs and healthy nutrition providers. Organized experience: Medications, Labs, Supplements, Fitness Gear. Fully integrated with the Kilow app and user flow. Opportunities for local suppliers to directly reach high-intent health consumers. Kilow invites investors, health brands, and suppliers to join the platform and be part of transforming the health landscape in Saudi Arabia. For partnerships or inquiries: partners@
Khaleej Times
08-08-2025
- Khaleej Times
From Ozempic to Mounjaro: Why Dubai restaurants are rethinking portion sizes
With skinny jabs and shrinking waistlines becoming the new normal, many fitness conscious are opting for smaller, selective palate. As a result, the food industry is looking for ways to reimagine the culinary scene. Banc, Downtown Dubai's newest hotspot, has just launched a brand-new menu for reduced appetites due to weightloss injections like Ozempic, Mounjaro and Wegovy. Ever since the news went out, it's generated a lot of interest. Everyone's calling it the 'Ozempic menu.' Banc's founders give us the lowdown on the facts, benefits and potential flipside of this trend. 'Let's clear one thing up right away — this isn't an 'Ozempic menu'. We're not doctors, and we're certainly not here to prescribe trends. But what we are seeing, both in London and now in Dubai, is a change in how people are eating. Appetite-suppressing medications like GLP-1s — which are prescribed by professionals for specific medical reasons — have a clear side effect: people just aren't eating as much. We were getting more and more guests asking, 'Can I get a smaller portion of this?' Some would share a main or skip dessert entirely. And we thought, why not meet people halfway? So we created The Mini Bancer – a menu featuring smaller portions of our most-popular dishes and drinks. It's all about flavour, just in less volume,' starts off Mazlum Topcu, co-founder of The Banc, located in Dubai and London. The founders noticed that in London, the guests still wanted the experience of dining out, but they were choosing differently. Hence, the idea of a 'skinny jab menu'. 'The average spending per head dipped, and that has a direct impact on the bottomline. But rather than fight it, we decided to get creative – without compromising on quality or creativity. Rather than a full three-course meal, they will order a few lighter plates,' says co-founder Can Topcu. The Mini Bancer menu is not just for people on GLP-1s (Type 2 diabetics); Banc is looking at a wider audience. 'We're seeing athletes, professionals, even foodies who just want to enjoy greater variety without feeling stuffed. It's also great for people with lighter appetites – or those trying to make more mindful choices without missing out on the pleasure of dining out,' explains Mazlum. The 'skinny jab menu' is for those with smaller appetites but still want to dine out and eat good food. Can Topcu adds, 'And let's be honest, Dubai is a city that loves a good night out, but it also cares deeply about health and image. This kind of menu fits naturally into that lifestyle. It's not about diet culture. It's about choice, balance, and still indulging in your favourite dishes – just in a way that suits how you're feeling that day. Guests don't want to feel left out or embarrassed by leaving half their meal or telling the table they are not drinking because they are on medication, have an early morning workout, or have other commitments.' By catering to GLP-1 users and health-conscious diners, Banc's 'inclusive' menu could be a game-changer. But what are the potential advantages and disadvantages of the 'Ozempic menu'? Will some diners feel self-conscious about ordering from a menu specifically designed for those on weight-loss medications? 'We see this as a new era for hospitality. It challenges us to think beyond 'bigger is better'. A miniature beverage or baklava bite dessert, they still use the same premium ingredients and techniques — it's not a shortcut – and the price reflects the smaller size. It's thoughtful, it's elegant, and frankly, it's a lot more fun than just saying 'no' to dessert,' says Mazlum. 'The upside is simple: it's inclusive. Whether you're on a medical programme, watching your portion sizes, or cutting back on drinking, this menu gives people the option to dine how they want. It's respectful of changing appetites, changing drinking habits, and a broader wellness mindset,' adds Can. The founders also believe that serving smaller portions could reduce food waste, aligning with sustainable dining practices. 'It's taken some adjusting. Smaller serves mean we've had to be smarter with curation, but the result is still high-impact and high-value. Sure, a few have called it a gimmick, but you can't please everyone. Introducing something new is always a gamble, but responding to guest feedback isn't trend-chasing – it's just good hospitality,' he says. After doing a trial run at their London location, the concept has made its UAE debut this month, blending The Banc's signature Mediterranean flavours with a narrower, health-conscious approach to dining. Terming their new menu as 'The Mini Bancer', this is a thoughtfully designed section of the menu, offering lighter, more intentional versions of the restaurant's most popular dishes and beverages. 'I think we're just trying to be honest with where people are right now. The way people eat is changing. Their habits, their appetites, their beverage choices – all of it. And as restaurateurs, we either adapt or get left behind. This isn't about Ozempic. It's about flexibility. Hospitality should never be one-size-fits-all,' explains Mazlum. Banc plans to tap into the UAE's growing market of health-conscious foodies who want nutritious and tasty options. 'We're deeply invested in Dubai, but the UAE has so many exciting markets. The feedback here has been incredible, and we're exploring opportunities to grow organically, without losing what makes The Banc special,' Can concludes.
Al Etihad
29-07-2025
- Al Etihad
Ozempic maker Novo's profit warning triggers $70 billion share rout
29 July 2025 19:13 COPENHAGEN (REUTERS)Investors knocked $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drugs Ozempic and Wegovy issued a profit warning and named a new CEO, as it battles rising competition in the obesity drug named Maziar Mike Doustdar as its new chief executive, turning to an experienced insider to revive sales and a share price hit by worries the company is falling behind in the weight-loss drug race it of a change at the top deepened a stock market rout, triggered after Novo slashed its outlook for 2025 sales growth to between 8% and 14%, from between 13% and 21% previously. Its shares plunged nearly 30% before paring some losses to trade down about 20% by has been hit by copycat versions of its weight-loss drugs - mixed or compounded by pharmacies. A crackdown on legal compounded versions of Wegovy in May could improve the situation, although Novo said illegal compounding Danish company said in a statement that the cut to its 2025 sales outlook was due to lower growth expectations in the second half in the United States, both for Wegovy and Ozempic in the GLP-1 diabetes drugmaker, which became Europe's most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as it looks to turn things around after the abrupt removal in May of CEO Lars Fruergaard its peak in June 2024, Novo was worth as much as $615 billion, but its shares have plunged on investor concerns about the company's experimental drug pipeline and its ability to navigate challenges in the US an Iranian-born, Austrian national, who grew up in the US, joined Novo in 1992 and will take on the new role on August currently serves as vice president for international operations, a role he took after leading the company's businesses first in the Middle East and then in Southeast Asia, Novo has lost its first-mover advantage in the United States this year to US rival Eli Lilly . The new chief executive's most urgent challenge, according to investors and analysts, is to revive Novo's performance in the US, the largest market by far for weight-loss drugs and where they are most profitable. Novo launched its weight-loss drug Wegovy nearly two and a half years before US rival Eli Lilly's Zepbound. But Zepbound prescriptions surpassed those of Wegovy this year by more than 100,000 a week.
